KR20180052126A - 활성 성분의 제어된, 지연된 방출을 갖는 제제 - Google Patents
활성 성분의 제어된, 지연된 방출을 갖는 제제 Download PDFInfo
- Publication number
- KR20180052126A KR20180052126A KR1020187010365A KR20187010365A KR20180052126A KR 20180052126 A KR20180052126 A KR 20180052126A KR 1020187010365 A KR1020187010365 A KR 1020187010365A KR 20187010365 A KR20187010365 A KR 20187010365A KR 20180052126 A KR20180052126 A KR 20180052126A
- Authority
- KR
- South Korea
- Prior art keywords
- active ingredient
- release
- tablet
- range
- rti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000004480 active ingredient Substances 0.000 title claims abstract description 166
- 239000000203 mixture Substances 0.000 title claims description 143
- 230000003111 delayed effect Effects 0.000 title abstract description 11
- 238000009472 formulation Methods 0.000 title description 38
- 238000000034 method Methods 0.000 claims abstract description 31
- 239000002552 dosage form Substances 0.000 claims abstract description 28
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 10
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 120
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 80
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 77
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 61
- 238000013265 extended release Methods 0.000 claims description 58
- 229960003712 propranolol Drugs 0.000 claims description 56
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 54
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 54
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 53
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 53
- 229960000278 theophylline Drugs 0.000 claims description 30
- 239000002245 particle Substances 0.000 claims description 29
- 239000011159 matrix material Substances 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 15
- 230000002035 prolonged effect Effects 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 11
- 239000002876 beta blocker Substances 0.000 claims description 10
- 229940097320 beta blocking agent Drugs 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000000314 lubricant Substances 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 235000012239 silicon dioxide Nutrition 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 6
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 claims description 5
- 238000009792 diffusion process Methods 0.000 claims description 5
- 230000003628 erosive effect Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 229960004604 propranolol hydrochloride Drugs 0.000 claims description 5
- 208000003870 Drug Overdose Diseases 0.000 claims description 4
- 206010033296 Overdoses Diseases 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 4
- 238000007906 compression Methods 0.000 claims description 4
- 230000006835 compression Effects 0.000 claims description 4
- 231100000725 drug overdose Toxicity 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 150000008064 anhydrides Chemical class 0.000 claims description 3
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 3
- 150000003840 hydrochlorides Chemical class 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 150000004682 monohydrates Chemical class 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical class [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 239000013618 particulate matter Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 25
- 239000003814 drug Substances 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 208000006673 asthma Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 239000003826 tablet Substances 0.000 description 104
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 71
- 235000019589 hardness Nutrition 0.000 description 32
- 238000000338 in vitro Methods 0.000 description 19
- 238000005259 measurement Methods 0.000 description 16
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 230000036470 plasma concentration Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000006185 dispersion Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 238000013270 controlled release Methods 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000000691 measurement method Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000019888 Vivapur Nutrition 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 239000007891 compressed tablet Substances 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000416 hydrocolloid Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000011362 coarse particle Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- AQHHHDLHHXJYJD-AWEZNQCLSA-N (2s)-1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol Chemical compound C1=CC=C2C(OC[C@@H](O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-AWEZNQCLSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 238000004438 BET method Methods 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002706 dry binder Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- -1 hiromellose Polymers 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000004407 iron oxides and hydroxides Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229930002161 purine alkaloid Natural products 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 229960004674 theophylline anhydrous Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15185028.6 | 2015-09-14 | ||
| EP15185028 | 2015-09-14 | ||
| EP15189045 | 2015-10-09 | ||
| EP15189045.6 | 2015-10-09 | ||
| PCT/EP2016/001430 WO2017045742A1 (de) | 2015-09-14 | 2016-08-25 | Formulierung mit kontrollierter, verzögerter wirkstoffreisetzung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180052126A true KR20180052126A (ko) | 2018-05-17 |
Family
ID=56855404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187010365A Withdrawn KR20180052126A (ko) | 2015-09-14 | 2016-08-25 | 활성 성분의 제어된, 지연된 방출을 갖는 제제 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10874615B2 (enExample) |
| EP (1) | EP3349733A1 (enExample) |
| JP (1) | JP6841819B2 (enExample) |
| KR (1) | KR20180052126A (enExample) |
| CN (1) | CN108024966A (enExample) |
| AU (1) | AU2016321659A1 (enExample) |
| CA (1) | CA2998422A1 (enExample) |
| WO (1) | WO2017045742A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160235709A1 (en) | 2012-08-31 | 2016-08-18 | Molecular product management LLC | Limited release lingual thioctic acid delivery systems |
| JP7238509B2 (ja) * | 2019-03-19 | 2023-03-14 | 三菱ケミカル株式会社 | 医薬錠剤 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58502097A (ja) * | 1981-12-18 | 1983-12-08 | キイ・フア−マシユ−テイカルズ・インコ−ポレイテツド | ポリビニルアルコ−ルおよびポリエチレングリコ−ルの拡張性格子 |
| EP0359746B1 (en) * | 1987-03-25 | 1992-06-03 | E.I. Du Pont De Nemours And Company | Use of vinyl alcohol homopolymers and copolymers for tableting active materials |
| US6495656B1 (en) * | 1990-11-30 | 2002-12-17 | Eastman Chemical Company | Copolyesters and fibrous materials formed therefrom |
| ES2079327B1 (es) * | 1994-12-13 | 1996-08-01 | Lilly Sa | Formulaciones farmaceuticas de cefaclor. |
| US5838571A (en) * | 1996-01-29 | 1998-11-17 | Alza Corporation | Tablet press monitoring and controlling method and apparatus |
| AU2001273231A1 (en) * | 2000-07-06 | 2002-01-21 | Delsys Pharmaceutical Corporation | Method for formulating healthcare products with enhanced stability |
| GB0113841D0 (en) * | 2001-06-07 | 2001-08-01 | Boots Co Plc | Therapeutic agents |
| US7022342B2 (en) * | 2002-03-28 | 2006-04-04 | Andrx Corporation, Inc. | Controlled release oral dosage form of beta-adrenergic blocking agents |
| US20060099256A1 (en) * | 2002-11-27 | 2006-05-11 | Price James C | Microspheres and related processes and pharmaceutical compositions |
| US7241838B2 (en) * | 2003-12-19 | 2007-07-10 | Eastman Chemical Company | Blends of aliphatic-aromatic copolyesters with ethylene-vinyl acetate copolymers |
| US7368503B2 (en) * | 2003-12-22 | 2008-05-06 | Eastman Chemical Company | Compatibilized blends of biodegradable polymers with improved rheology |
| US20080152595A1 (en) * | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
| WO2007090883A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
| US9238073B2 (en) * | 2006-04-12 | 2016-01-19 | Wyeth Llc | Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive |
| NZ584521A (en) * | 2007-10-10 | 2011-03-31 | Avantor Performance Mat Inc | Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof |
| PT2177213E (pt) * | 2008-09-17 | 2013-02-21 | Siegfried Ltd | Granulado contendo nicotina |
| EP2498764B1 (en) * | 2009-11-09 | 2017-09-06 | Spotlight Technology Partners LLC | Fragmented hydrogels |
| JP2013241341A (ja) * | 2012-05-17 | 2013-12-05 | Nisshin Kasei Kk | マトリックス製剤用基剤、及び該基剤を用いた徐放性製剤 |
| GB201412413D0 (en) * | 2014-07-11 | 2014-08-27 | Revolymer Uk Ltd | Encapsulated benefit agent particles |
| AU2015295847B2 (en) * | 2014-07-30 | 2020-06-18 | Merck Patent Gmbh | Pulverulent, directly compressible types of polyvinyl alcohol |
-
2016
- 2016-08-25 AU AU2016321659A patent/AU2016321659A1/en not_active Abandoned
- 2016-08-25 WO PCT/EP2016/001430 patent/WO2017045742A1/de not_active Ceased
- 2016-08-25 KR KR1020187010365A patent/KR20180052126A/ko not_active Withdrawn
- 2016-08-25 JP JP2018513528A patent/JP6841819B2/ja not_active Expired - Fee Related
- 2016-08-25 CA CA2998422A patent/CA2998422A1/en not_active Abandoned
- 2016-08-25 US US15/759,674 patent/US10874615B2/en active Active
- 2016-08-25 EP EP16760385.1A patent/EP3349733A1/de not_active Withdrawn
- 2016-08-25 CN CN201680053419.0A patent/CN108024966A/zh active Pending
-
2020
- 2020-04-21 US US16/854,516 patent/US20200246270A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3349733A1 (de) | 2018-07-25 |
| JP6841819B2 (ja) | 2021-03-10 |
| WO2017045742A1 (de) | 2017-03-23 |
| CA2998422A1 (en) | 2017-03-23 |
| AU2016321659A1 (en) | 2018-05-10 |
| CN108024966A (zh) | 2018-05-11 |
| JP2018530538A (ja) | 2018-10-18 |
| US20190038562A1 (en) | 2019-02-07 |
| US10874615B2 (en) | 2020-12-29 |
| US20200246270A1 (en) | 2020-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6629835B2 (ja) | 直接圧縮可能なポリビニルアルコール | |
| JP6706245B2 (ja) | 微結晶性セルロースを含む直接圧縮可能な組成物 | |
| JP2022000430A (ja) | 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物 | |
| US11040012B2 (en) | Pulverulent, directly compressible polyvinyl alcohol grades | |
| AU2012288632B2 (en) | New (trimethoxyphenylamino)pyrimidinyl formulations | |
| US20200246270A1 (en) | Formulation having controlled, delayed release of active ingredient | |
| EP2077822B1 (en) | Oxcarbazepine-containing oral formulation and a process to obtain the same | |
| KR20190095373A (ko) | 연장된 활성 물질 전달을 갖는 정제를 제조하기 위한 직접 타정성 매트릭스 | |
| US20180250233A1 (en) | Tablets having media independent active substance delivery | |
| EP4410278A1 (en) | Pharmaceutical composition comprising enavogliflozin | |
| EP2968167A1 (en) | Dosage form comprising crizotinib | |
| HK40026299B (en) | Bromocriptine formulations | |
| HK40026299A (en) | Bromocriptine formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180412 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination |